NIH R01 · 2024
Next generation of AAV vector targeting adipose tissue
Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Adeno-associated viral (AAV) vectors are mainstream delivery platforms in gene therapy because of its safety profile and promising results in clinical trials. AAV has been successfully used to deliver transgenes to liver, heart, skeletal muscle, brain, and eye. Yet AAV-mediated gene transfer to adipose tissue is left far behind due to the low transduction efficiency and tropism of natural AAV serotypes. Our previous study demonstrates that an engineered hybrid capsid Rec2, transduces adipose tissue with superior efficiency than natural AAV serotypes. One…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.